Aspirin may reduce deaths in severe COVID-19 ? Medical News ...

The researchers compared the outcomes for these individuals with those for the 314 people who did not take aspirin.Among those taking aspirin, the median daily dose was 81 milligrams, and the median length of treatment was 6 days.In their analysis of the data, the researchers accounted for other variables that scientists have shown to affect the severity of COVID-19, including age, sex, body mass index, race, hypertension, and diabetes.After these adjustments, aspirin use was associated with a 43% reduced risk of intensive care unit admission, a 44% reduced risk of mechanical ventilation, and a 47% reduced risk of dying in the hospital.While there was no evidence that aspirin increased the risk of bleeding, the authors recommend caution: “Until a randomized controlled trial of aspirin is performed, it is imperative to exercise cautious optimism and deliberately balance aspirin’s known risks against its potential benefits in patients afflicted by COVID-19.”Interestingly, the researchers found no difference in overt thrombosis between the aspirin and non-aspirin groups.